Antibacterial Therapies Drug Market

1
Antibacterial Therapies Drug Market
2
Summary

• The antibacterial drug market covers the drugs
  used in the prophylaxis treatment of bacterial
  infections. With a growing global concern over
  antimicrobial resistance and its progressive
  growth, there is a pronounced need for innovation
  within thismarket.
• There are over 1400 products in active
  development in the antibacterial drug market,
  with the majority of products being small
  molecules. Vaccines are also wellestablished
  within the market, and accounts for approximately
  25 of the pipeline.
• Currently, drugs for the prevention of bacterial
  infections are typically vaccineswhich help to
  train the bodys immune system to fight off
  bacterial infections caused by specific bacterial
  strains. However, several prophylactic monoclonal
  antibodies are now in the pipeline and may impact
  the market in the near future.

3
(No Transcript)
4

• Drugs for the treatment of bacterial infections
  are slightly more varied. Mostcommon are
  beta-lactam antibiotics, such as penicillin, and
  protein synthesisinhibitors. However, bacterial
  resistance has reduced the efficacy of many of
  thesedrugs. As a result the pipeline includes a
  variety of new-generation protein synthesis
  inhibitors and beta-lactam/beta-lactamase
  inhibitor combination drugs, which areactive
  against currently hard to treat bacterial
  strains.
• The report provides comprehensive information on
  the pipeline developmentlandscape for Pneumonia,
  Methicillin-resistant staphylococcus aureus
  (MRSA) and Tuberculosis, from Discovery through
  to the Pre-Registration stage. This includesan
  analysis of products by stage of development,
  molecular target, mechanism ofaction (MoA),
  route of administration (RoA) and molecule type.
  A list of all products in development is
  provided, including dormant and discontinued
  projects. Finally, the report provides an
  overview of key players involved in the
  development ofproducts in this area, and
  outlines recent updates and press releases in the
  field.

5
Scope

• Which companies are the most active within the
  pipeline for antibacterial drugs?
• Which pharmaceutical approaches are the most
  prominent at each stage of thepipeline and
  within each indication?
• To what extent do universities and institutions
  play a role within this pipeline,compared to
  pharmaceutical companies?
• What are the most important RD milestones and
  data publications to havehappened in this
  disease area?

6
Reasons to buy

• Understand the overall pipeline, with an
  at-a-glance overview of all products
  intherapeutic development for each indication
• Assess the products in development in granular
  detail, with an up-to-dateoverview of each
  individual pipeline program in each indication,
  and acomprehensive picture of recent updates and
  milestones for each
• Analyze the companies, institutions and
  universities currently operating in thepipeline,
  and the products being fielded by each of these
• Understand the composition of the pipeline in
  terms of molecule type, molecular target,
  mechanism of action and route of administration

7
Full Reports
Antibacterial Therapies DrugMarket
Contact us atBharat Book Bureau Tel 91 22
27810772 / 27810773 Emailpoonam_at_bharatbook.com Ou
r Bloghttps//www.bharatbook.com/blog/ Twitterht
tps//twitter.com/researchbook Facebookhttps//ww
w.facebook.com/BharatBook3B LinkedInhttp//www.li
nkedin.com/company/bharat-book-bureau
8
THANK YOU